Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Program helping patients self-regulate strong-opioid use has potential for NHS, study shows (opens in a new tab)

medicalxpress.com · 2026-10-09

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredMore than 600 patients with nonmalignant chronic pain took part in a yearlong clinical trial, and 29% in the support group were off strong opioids entirely after 12 months, compared with 7% receiving standard care.View evidenceHide evidence

As stated29% vs 7% after 12 months; more than 600 patients

Why this verdict

The abstract-level profile verifies the general trial size and duration: 608 participants from 191 primary care centres followed up for up to 12 months. It also supports reduced opioid consumption generally. However, the specific clinical outcome numbers stated by the story—29% off strong opioids versus 7% under standard care—are not reported in the supplied abstract-level paper profile, so that magnitude cannot be verified at this depth.

1

Study evidence

Within the 12-month trial follow-up, the I-WOTCH intervention was associated with higher healthcare costs than best usual care.

“Within-trial cost-consequence (CCA) and model-based cost-effectiveness analyses (CEA), over one year and lifetime horizons, respectively.”
2

Study evidence

Within-trial (12 months) analysis: I-WOTCH incurred higher costs and produced similar health-related quality of life (HRQoL) compared with best usual care.

“We used a probabilistic state-transition model to predict expected quality-adjusted life years (QALYs) and costs (in UK £) of each strategy over the lifetime of an individual.”
Claim 2 of 5Not coveredResearchers now want to observe people with nonmalignant chronic pain over a longer period to see whether the habits remain lifelong and whether they can use, taper off or quit strong opioids at will.View evidenceHide evidence

Why this verdict

The profile supports a general need for further research because lifetime results depend on extrapolation, treatment-effect waning assumptions, and substantial decision uncertainty. But the more specific claim that researchers now want to observe whether habits remain lifelong and whether patients can use, taper, or quit strong opioids 'at will' is not stated in the abstract-level profile, so it is not verifiable at this depth.

1

Study evidence

Within-trial (12 months) analysis: I-WOTCH incurred higher costs and produced similar health-related quality of life (HRQoL) compared with best usual care.

“We used a probabilistic state-transition model to predict expected quality-adjusted life years (QALYs) and costs (in UK £) of each strategy over the lifetime of an individual.”
2

Study evidence

Model results were sensitive to structural assumptions, explicitly cohort starting age and the treatment-effect weaning rate.

“Results were sensitive to structural assumptions in the model (i.e. cohort starting age, treatment effect weaning rate).”
Claim 3 of 5SupportedA new support program can increase the number of patients who successfully self-regulate their long-term intake of strong opioid painkillers without worsening their quality of life.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that I-WOTCH was evaluated against best usual care in an RCT-derived dataset for people with chronic non-malignant pain, and that the intervention reduced opioid consumption without worsening perceived pain, with similar EQ-5D health-related quality-of-life outcomes at 12 months. The story’s causal framing is broadly consistent with the randomized-trial context, although the exact wording about patients “self-regulating” is more journalistic than the paper profile’s wording.

1

Study evidence

Within the 12-month trial follow-up, the I-WOTCH intervention was associated with higher healthcare costs than best usual care.

“Within-trial cost-consequence (CCA) and model-based cost-effectiveness analyses (CEA), over one year and lifetime horizons, respectively.”
2

Study evidence

Within-trial (12 months) analysis: I-WOTCH incurred higher costs and produced similar health-related quality of life (HRQoL) compared with best usual care.

“We used a probabilistic state-transition model to predict expected quality-adjusted life years (QALYs) and costs (in UK £) of each strategy over the lifetime of an individual.”
Claim 4 of 5SupportedThe economic evaluation of the I-WOTCH program suggests that although it costs more upfront, its long-term benefits could make it good value for money for the NHS.View evidenceHide evidence

Why this verdict

The paper profile supports that I-WOTCH had higher short-term costs but, in a lifetime model, produced higher QALYs and a base-case ICER of £29,543/QALY, leading the authors to conclude it may be cost-effective on average. The story appropriately hedges this as 'could' be good value, though the profile also emphasizes substantial decision uncertainty.

1

Study evidence

Within-trial (12 months) analysis: I-WOTCH incurred higher costs and produced similar health-related quality of life (HRQoL) compared with best usual care.

“We used a probabilistic state-transition model to predict expected quality-adjusted life years (QALYs) and costs (in UK £) of each strategy over the lifetime of an individual.”
2

Study evidence

Model results were sensitive to structural assumptions, explicitly cohort starting age and the treatment-effect weaning rate.

“Results were sensitive to structural assumptions in the model (i.e. cohort starting age, treatment effect weaning rate).”
Claim 5 of 5SupportedThe analysis, published in the journal Addiction, says the program initially increases health care costs over the first year because patients need extra medical support while tapering off medication.View evidenceHide evidence

Why this verdict

The profile supports that the within-trial 12-month economic analysis found higher healthcare costs for I-WOTCH than best usual care. It also describes the intervention as including group sessions plus ongoing one-to-one nursing and lay support during follow-up, which is consistent with the story’s explanation that extra support during tapering drove upfront costs. The journal name itself is not independently evidenced in the supplied profile, but the substantive cost claim is supported.

1

Study evidence

Within the 12-month trial follow-up, the I-WOTCH intervention was associated with higher healthcare costs than best usual care.

“Within-trial cost-consequence (CCA) and model-based cost-effectiveness analyses (CEA), over one year and lifetime horizons, respectively.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The lifetime cost-effectiveness result is model-based, not directly observed over a lifetime; it extrapolates from 12-month trial data and uses external literature for opioid-related excess mortality and fracture risks.

    The story mentions that long-term benefits could make the program good value and notes a need for longer-term evidence, but it does not clearly explain that the lifetime value-for-money conclusion depends on a probabilistic model extrapolated from 12-month data and external risk estimates.

    From Probabilistic state-transition model (lifetime-horizon CEA)

  • Decision uncertainty was substantial: probabilistic sensitivity analysis found about a 50% probability that I-WOTCH is cost-effective across willingness-to-pay thresholds from £0 to £100,000/QALY.

    This is an interpretation-changing limitation for the value-for-money claim. The story hedges the economic conclusion and mentions need for stronger long-term evidence, but it does not convey the paper’s central uncertainty result that the probability of cost-effectiveness was only about 50%.

    From Probabilistic state-transition model (lifetime-horizon CEA); Probabilistic sensitivity analysis and deterministic scenar

  • Model results were sensitive to structural assumptions, including cohort starting age and the treatment-effect weaning rate.

    The story notes that long-term durability remains uncertain, but it does not report the specific structural sensitivity of the model to starting age and treatment-effect waning assumptions.

    From Probabilistic sensitivity analysis and deterministic scenario analyses

3 things the story did carry across
  • The paper is primarily an economic evaluation of I-WOTCH versus best usual care, using 12-month RCT follow-up data and a lifetime model from a UK NHS/PSS perspective.
  • Within the 12-month trial horizon, I-WOTCH incurred higher healthcare costs and had similar EQ-5D health-related quality-of-life outcomes compared with best usual care.
  • The base-case modeled ICER was £29,543 per QALY, with higher lifetime costs and higher lifetime QALYs for I-WOTCH versus best usual care.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in silico

1Lead resultin silicoEstimate the long-term (lifetime-horizon) cost-effectiveness of I-WOTCH versus BUC by extrapolating RCT outcomes in a probabilistic state-transition model incorporating opioid-related excess mortality and fracture risks from external literature.Probabilistic state-transition model (lifetime-horizon CEA)Expand

In plain English

Model-based lifetime cost-effectiveness analysis (probabilistic state-transition model) extrapolating outcomes from the I-WOTCH randomized trial and incorporating literature-based opioid-related excess mortality and fracture risks to estimate incremental costs, QALYs, and probability of cost-effectiveness for the I-WOTCH intervention versus best usual care (BUC). Base-case lifetime ICER £29,543 per QALY; results sensitive to structural assumptions and subject to decision uncertainty.

Key findings

  • Within-trial (12 months) analysis: I-WOTCH incurred higher costs and produced similar health-related quality of life (HRQoL) compared with best usual care.
  • Lifetime-horizon model: I-WOTCH produced higher lifetime costs and higher lifetime QALYs versus BUC, with a base-case incremental cost-effectiveness ratio of £29,543 per QALY (2019 prices).£29,543/QALY
“We used a probabilistic state-transition model to predict expected quality-adjusted life years (QALYs) and costs (in UK £) of each strategy over the lifetime of an individual.”
What this piece can’t prove
  • Lifetime extrapolation is based on 12-month trial data, introducing uncertainty in long-term projections.
  • Key epidemiologic inputs (opioid-related excess mortality and fracture rates) were sourced from external literature; their applicability influences results.
  • Results were sensitive to structural model assumptions (e.g., cohort starting age, treatment-effect waning), contributing to decision uncertainty.
2secondary dataAssess the short-term (within-trial) economic consequences of the I-WOTCH group-based opioid-withdrawal support intervention versus best usual care (BUC) for people with chronic non-malignant pain, using 12-month RCT follow-up data from the UK NHS/PSS perspective.Within-trial cost-consequence analysis (12-month horizon)Expand

In plain English

Within-trial (12-month) cost-consequence analysis using individual-level resource-use and EQ-5D data from the I-WOTCH randomized trial (N=608) found that the I-WOTCH group-based opioid-withdrawal support intervention incurred higher healthcare costs and produced similar health-related quality of life (EQ-5D) outcomes compared with best usual care over the 12-month follow-up (UK NHS/PSS perspective).

Key findings

  • Within the 12-month trial follow-up, the I-WOTCH intervention was associated with higher healthcare costs than best usual care.
  • Health-related quality of life (EQ-5D) at 12 months was similar between I-WOTCH and best usual care.
“Within-trial cost-consequence (CCA) and model-based cost-effectiveness analyses (CEA), over one year and lifetime horizons, respectively.”
What this piece can’t prove
  • Analysis is limited to a 12-month within-trial horizon and therefore does not capture longer-term mortality or morbidity benefits that might result from reduced opioid exposure.
  • Abstract does not report numerical incremental cost estimates, confidence intervals, or statistical testing for within-trial cost and EQ-5D differences.
  • Decision uncertainty remains (authors state further research is warranted), but the abstract provides limited detail on uncertainty specific to the within-trial economic results.
3in silicoCharacterize decision uncertainty and key drivers of cost-effectiveness (e.g., structural assumptions such as cohort starting age and treatment-effect weaning rate) via sensitivity/uncertainty analyses.Probabilistic sensitivity analysis and deterministic scenario analysesExpand

In plain English

The lifetime model-based cost-effectiveness analysis incorporated deterministic (structural) scenario analyses and a probabilistic sensitivity analysis (PSA). The authors report that model results were sensitive to structural assumptions (explicitly citing cohort starting age and the treatment-effect weaning rate) and that the PSA produced an approximately 50% probability that the I-WOTCH intervention is cost‑effective versus best usual care across willingness-to-pay thresholds from £0 to £100,000/QALY. These uncertainty analyses informed the authors' conclusion that I-WOTCH appears cost‑effective on average but that decision uncertainty remains substantial, warranting further research.

Key findings

  • Model results were sensitive to structural assumptions, explicitly cohort starting age and the treatment-effect weaning rate.
  • Probabilistic sensitivity analysis indicated a 50% probability that I-WOTCH is cost-effective versus best usual care across willingness-to-pay thresholds from £0 to £100,000 per QALY.50% probability
“Results were sensitive to structural assumptions in the model (i.e. cohort starting age, treatment effect weaning rate).”
What this piece can’t prove
  • Abstract does not report the PSA parameter distributions, number of simulations, or a threshold-specific cost-effectiveness acceptability curve.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 38 candidate papers

Candidate

Augmented and Virtual Reality for Workforce Training: A Smart Engagement Approach in Manufacturing Organizations

2026 13Th International Conference on Computing for Sustainable Global Development (INDIACom) · 2026 · Crossref

Source (opens in a new tab)
Candidate

SOCIAL MEDIA ADDICTION, FEAR OF MISSING OUT AND DEPRESSIVE SYMPTOMS AMONG UNIVERSITY STUDENTS

Scholarly Journal · 2026 · Crossref

Source (opens in a new tab)
Candidate

PARENTING STYLES AND ADOLESCENT EMOTIONAL WELL-BEING: THE MEDIATING ROLE OF SOCIAL MEDIA ADDICTION

Scholarly Journal · 2026 · Crossref

Source (opens in a new tab)
Candidate

Social Media Addiction, Anxiety, and Academic Performance Among Young Adults | Meritorious Journal of Social Sciences and Management

Scholarly Journal · 2026 · Crossref

Source (opens in a new tab)

And 32 more candidates considered.